459 related articles for article (PubMed ID: 10914818)
1. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
2. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer.
Caldés T; Perez-Segura P; Tosar A; de La Hoya M; Diaz-Rubio E
Teratog Carcinog Mutagen; 2000; 20(5):283-91. PubMed ID: 10992275
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability in ductal carcinoma in situ of the breast.
Walsh T; Chappell SA; Shaw JA; Walker RA
J Pathol; 1998 May; 185(1):18-24. PubMed ID: 9713355
[TBL] [Abstract][Full Text] [Related]
5. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
8. Mutation at chromosome 11q23 in human non-familial breast cancer: a microdissection microsatellite analysis.
Koreth J; Bethwaite PB; McGee JO
J Pathol; 1995 May; 176(1):11-8. PubMed ID: 7616353
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
10. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history.
Keller G; Rudelius M; Vogelsang H; Grimm V; Wilhelm MG; Mueller J; Siewert JR; Höfler H
Am J Pathol; 1998 May; 152(5):1281-9. PubMed ID: 9588896
[TBL] [Abstract][Full Text] [Related]
12. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
13. [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
Fu Q; Yao GY; Tang XL; Chen LR; Zheng ZX
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):34-40. PubMed ID: 17575691
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
16. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
17. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
18. Replication error in human breast cancer: comparison with clinical variables and family history of cancer.
Huiping C; Johannsdottir JT; Arason A; Olafsdottir GH; Eiriksdottir G; Egilsson V; Ingvarsson S
Oncol Rep; 1999; 6(1):117-22. PubMed ID: 9864413
[TBL] [Abstract][Full Text] [Related]
19. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
